partnering David Setboun, Country President of AstraZeneca, discusses the opportunities that the Portuguese market can bring despite economic downturn, and the future of the Portuguese affiliate in expanding to new therapeutic areas. In what way do you think the pharmaceutical industry can act as an engine of economic recovery and development…
Government Regulation You have been in Taiwan now for ten months. What are the most important characteristics of this market from your perspective, and what surprised you most about Taiwan? Taiwan is a highly developed economy to start with; it is a very established market, with a very good healthcare system. The…
Generics Janssen has historically had a very strong focus on emerging markets. In today’s world, where growth for the pharmaceutical industry overwhelmingly comes from emerging markets, where do we find the Nordics? What is the relevance of the Nordics for the country’s global footprint? Jansen has preserved the cluster model. We…
Generics Tom Rönnlund discusses the current state of the pharmaceutical industry in the Nordics in this time of austerity, and offers opinions on reference pricing and cooperation in the region. How have the markets in Denmark and Sweden evolves over the past five years, since the financial crisis started and austerity…
Generics Fergal Murphy, Chairman of the Association of Pharmaceutical Manufacturers in Ireland, discusses with pharamaboardroom.com the difficulties in such a small market and how the industry is adapting to the needs of Ireland by working closely with the government to find the right price point for products and increasing awareness of…
Espíndola International Consultants An expert in trade and regulatory issues relating to the pharmaceutical industry in Colombia, the senior partner of Espíndola International Consultants offers his opinions on the steps taken by the Colombian authorities to improve quality and reduce corruption in the sector, as well as discussing the steps to maintain cost containment…
Aspen The Aspen Group identified Latin America as a “large developing market where it can leverage its substantial intellectual property portfolio and manufacturing infrastructure”. What was the original strategy behind getting the best from the Mexican market – specifically with the acquisition of the Latin America business from India-based Strides Arcolab…
Dr Reddy's Laboratories Looking back at the company’s recent challenges, we see a very tough 2009, largely due to the Betapharm acquisition and the subsequent changes in German regulations. How do you explain the situation there and what measures did you take to turn the situation around? Germany, and in particular the Betapharm…
generics “The ball is in the hands of the government,” according to Giorgio Foresti, general manager of Ratiopharm. “Once aware of the opportunities created by generics, politicians will have to make hard decisions.” Until now, generics prescriptions were limited by strong links between innovators and doctors, and price alignment trends reducing…
See our Cookie Privacy Policy Here
